Former FDA commissioners urge Heidi Overton to strengthen agency amid global competition
Former FDA commissioners told a Senate health committee hearing that nominee Heidi Overton has a chance to improve the Food and Drug Administration.
Nominee faces regulatory challenges
Commissioners stated that biomedical innovation is moving faster than ever before. They noted that institutions supporting this progress are currently under significant strain. Overton will address these issues during her confirmation hearing on Thursday.
China advances clinical trials
Reports indicate that China now starts more Phase 1 trials than the United States. The country also moves new compounds into testing phases more quickly than American counterparts. Other nations are similarly advancing their own biomedical enterprises at a rapid pace.
Opportunity for leadership
The commissioners believe Overton possesses the experience to bridge existing divides in the field. She has an opportunity to demonstrate these goals before the Senate health committee. Consistent support could help build both regulatory expertise and clinical development capacity.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.